Company intelligence / Profile preview

Longmaster

Shanghai, Shanghai, Chinaenglish.guiyang.gov.cn ↗

Ownership: Private
Development stage: Phase 2

Overview

LongBio Pharma has developed multiple proprietary platforms for biologics discovery and development. Its lead programs include a next-generation IgE monoclonal antibody and a bi-functional complement inhibitor currently in Phase II trials. The company also has early-stage assets in hematology, nephrology, neurology, ophthalmology, oncology, and gene therapy.

Therapeutic areas: NephrologyOncologyRare DiseasesImmunologyHematologyOphthalmologyNeurology
Modalities: Monoclonal antibodyFc-fusion protein (Biologic)Complement inhibitor (Biologic)Cytokine (Biologic)Gene therapy
Industry: Biotech

Drug pipeline

5 assets

ensovibep

Phase 2/3

Indications: COVID-19

4 more assets in the full pipeline.

Request access →

Partnerships

Partners for domestic and international market access are mentioned but not named specifically

Beyond the preview

Go deeper on Longmaster.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Longmaster.

Explore the full profile